Finalist
Open Horizons: Raising Standards of Care in Immune-Mediated Skin Diseases
by Lucid Group for AbbVie
Summary of work
Immune-mediated skin diseases (IMSDs) such as psoriasis (PsO), atopic dermatitis (AD) and hidradenitis suppurativa (HS) are associated with significant patient burden and unmet needs. Clinical consensus advises that dermatologists aim for high treatment targets to minimise psychosocial sequelae and comorbidities. However, dermatologists report a lack of confidence in managing disease impact.
AbbVie and Lucid partnered to develop ‘Open Horizons’ – a global initiative that meaningfully addresses unmet needs and raises the standard of care in IMSDs, specifically PsO, AD and HS. We generated insights on disease burden, unmet patient and healthcare professionals’ (HCP) needs, and barriers to improving care. From these insights, we identified key objectives to effect change through a multi-interventional initiative, including a live global summit cascading to national events, driving peer-to-peer exchange and application of learning. Through a behavioural survey, we demonstrated clear intent of HCPs to change behaviour in line with the key objectives of the initiative.
Judges’ comments
The work from AbbVie and Lucid Group was a really good programme with a well-outlined unmet need. The strategy was clearly defined and tailored to the objectives. It showed a marked improvement, ensuring that this was furthered by the six-month follow-up survey.
